PriceTargets.com logo

Aimmune Therapeutics - AIMT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$34.49 As of 10/13/2020 01:00 AM ET
+0 (0.00%)
Get New Aimmune Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AIMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AIMT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aimmune Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $34.49.

This chart shows the closing price for AIMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Aimmune Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2020Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $34.50Low
9/1/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$24.00 ➝ $35.00Low
8/31/2020WedbushDowngradeOutperform ➝ Neutral$66.00 ➝ $34.50Low
8/31/2020Piper SandlerDowngradeOverweight ➝ Neutral$60.00 ➝ $34.50N/A
8/3/2020WedbushReiterated RatingBuy$66.00Medium
7/31/2020Cantor FitzgeraldLower Target$32.00 ➝ $24.00High
7/30/2020Stifel NicolausReiterated RatingHold$18.00High
7/29/2020Credit Suisse GroupLower TargetNeutral$19.00 ➝ $15.00Low
7/13/2020CowenInitiated CoverageOutperform$35.00Medium
5/13/2020WedbushReiterated RatingBuy$66.00High
5/13/2020Credit Suisse GroupLower TargetNeutral$29.00 ➝ $19.00High
5/12/2020HC WainwrightLower TargetNeutral$30.00 ➝ $15.00Medium
5/11/2020Stifel NicolausReiterated RatingHold$32.00 ➝ $20.00Low
3/23/2020Cantor FitzgeraldLower TargetOverweight$64.00 ➝ $32.00High
3/18/2020WedbushReiterated RatingBuy$66.00Low
3/18/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
3/17/2020Robert W. BairdLower TargetOutperform$64.00 ➝ $58.00High
3/3/2020WedbushReiterated RatingBuy$66.00N/A
3/2/2020Credit Suisse GroupLower Target$34.00 ➝ $29.00High
3/2/2020Stifel NicolausLower TargetHold$34.00 ➝ $32.00High
2/28/2020HC WainwrightReiterated RatingNeutral$33.00 ➝ $30.00Medium
2/26/2020WedbushReiterated RatingBuy$74.00Medium
2/3/2020Robert W. BairdReiterated RatingBuy$64.00High
2/3/2020WedbushBoost TargetOutperform$79.00 ➝ $81.00High
2/3/2020JMP SecuritiesBoost TargetMarket Outperform$40.00 ➝ $44.00High
2/3/2020Cantor FitzgeraldBoost TargetOverweight$55.00 ➝ $64.00High
2/2/2020Stifel NicolausReiterated RatingHold$34.00High
1/23/2020Roth CapitalBoost Target$45.00 ➝ $50.00Medium
1/21/2020WedbushReiterated RatingBuy$79.00Medium
1/9/2020WedbushReiterated RatingBuy$79.00Medium
12/19/2019HC WainwrightInitiated CoverageNeutral$33.00Low
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$31.59 ➝ $30.00Medium
10/31/2019WedbushReiterated RatingBuyMedium
10/25/2019The Goldman Sachs GroupSet TargetHold$27.00N/A
10/9/2019Piper Sandler CompaniesSet TargetBuy$60.00N/A
9/16/2019WedbushReiterated RatingHold ➝ Outperform$79.00Medium
9/16/2019Stifel NicolausUpgradePositiveHigh
9/11/2019Stifel NicolausBoost TargetHold$24.00 ➝ $30.00High
8/21/2019WedbushSet TargetBuy$79.00High
8/18/2019Stifel NicolausReiterated RatingHold$24.00High
8/9/2019Royal Bank of CanadaLower TargetOutperform$50.00Medium
7/12/2019Roth CapitalInitiated CoverageBuy ➝ Buy$45.00Low
7/11/2019WedbushSet TargetBuy$79.00Medium
7/2/2019WedbushReiterated RatingBuy$79.00Low
6/6/2019WedbushReiterated RatingOutperform$79.00Medium
5/24/2019WedbushSet TargetBuy$79.00Low
5/21/2019Credit Suisse GroupInitiated CoverageOutperform$36.00 ➝ $30.00High
5/9/2019WedbushReiterated RatingBuy$79.00Low
5/9/2019Cantor FitzgeraldReiterated RatingBuy$45.00Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aimmune Therapeutics logo
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $34.49
Low: $34.49
High: $34.49

50 Day Range

MA: $34.46
Low: $34.30
High: $34.59

52 Week Range

Now: $34.49
Low: $10.09
High: $37.00

Volume

N/A

Average Volume

1,714,599 shs

Market Capitalization

$2.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Aimmune Therapeutics?

The following Wall Street research analysts have issued research reports on Aimmune Therapeutics in the last twelve months:
View the latest analyst ratings for AIMT.

What is the current price target for Aimmune Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aimmune Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aimmune Therapeutics in the next year.
View the latest price targets for AIMT.

What is the current consensus analyst rating for Aimmune Therapeutics?

Aimmune Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AIMT.

What other companies compete with Aimmune Therapeutics?

Other companies that are similar to Aimmune Therapeutics include Ra Pharmaceuticals, TG Therapeutics, Dyne Therapeutics, Arvinas and Vera Therapeutics. Learn More about companies similar to Aimmune Therapeutics.

How do I contact Aimmune Therapeutics' investor relations team?

Aimmune Therapeutics' physical mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company's listed phone number is 650-614-5220 and its investor relations email address is [email protected]. The official website for Aimmune Therapeutics is www.aimmune.com. Learn More about contacing Aimmune Therapeutics investor relations.